TY - JOUR

T1 - Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease

T2 - The DECODE-CKD Trial

AU - Bartholdy, Katja Vu

AU - Johansen, Niklas Dyrby

AU - Landler, Nino

AU - Skaarup, Kristoffer Grundtvig

AU - Jensen, Jesper

AU - Bressendorff, Iain

AU - Schou, Morten

AU - Christensen, Jacob

AU - Feldt-Rasmussen, Bo

AU - Vaduganathan, Muthiah

AU - Solomon, Scott

AU - Haynes, Richard

AU - Persson, Frederik

AU - Rossing, Peter

AU - Køber, Lars

AU - Zannad, Faiez

AU - Hansen, Ditte

AU - Biering-Sørensen, Tor

N1 - Publisher Copyright: © 2022 by the American Society of Nephrology.

PY - 2023

Y1 - 2023

N2 - Background SGLT2 inhibitors, originally developed as glucose-lowering agents for treatment of type 2 diabetes, have been shown to have cardio- and kidney-protective effects among CKD patients with and without diabetes. However, the mechanisms remain largely unknown. Methods Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD) is an investigator-initiated, prospective, single-center, randomized, placebo-controlled trial evaluating the effects of 6 months of treatment with 10 mg of dapagliflozin compared with placebo on cardiac structure and function in 222 adults with CKD. Results The primary objective was to assess whether dapagliflozin improves left ventricular mass index. Secondary and exploratory end points include changes in cardiac and kidney markers, quality of life, depressive symptoms, and cognitive function. Conclusions This is the first study to address the effects of SGLT2 inhibitors on cardiac structure and function in patients with CKD. The results will provide valuable insights into the mechanisms underlying the cardioprotective benefits of SGLT2 inhibitors in patients with CKD.

AB - Background SGLT2 inhibitors, originally developed as glucose-lowering agents for treatment of type 2 diabetes, have been shown to have cardio- and kidney-protective effects among CKD patients with and without diabetes. However, the mechanisms remain largely unknown. Methods Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD) is an investigator-initiated, prospective, single-center, randomized, placebo-controlled trial evaluating the effects of 6 months of treatment with 10 mg of dapagliflozin compared with placebo on cardiac structure and function in 222 adults with CKD. Results The primary objective was to assess whether dapagliflozin improves left ventricular mass index. Secondary and exploratory end points include changes in cardiac and kidney markers, quality of life, depressive symptoms, and cognitive function. Conclusions This is the first study to address the effects of SGLT2 inhibitors on cardiac structure and function in patients with CKD. The results will provide valuable insights into the mechanisms underlying the cardioprotective benefits of SGLT2 inhibitors in patients with CKD.

KW - cardiology

KW - CKD

KW - echocardiography

KW - RCT

KW - SGLT2-inhibitors

U2 - 10.34067/KID.0006982022

DO - 10.34067/KID.0006982022

M3 - Journal article

C2 - 36649484

AN - SCOPUS:85162983421

VL - 4

SP - 143

EP - 149

JO - Kidney360

JF - Kidney360

SN - 2641-7650

IS - 2

ER -